This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.

2. Presented By :
Syed Faraz Rizvi
MBA-II(Karachi University)

3. Introduction
Vision & Mission Statement
Core Values
Products
SWOT Analysis
Achievements
Industry Info
Competitors
Market Share
Financial Data

4. A Global Broad-Based Health Care Company.
Founded in USA about 120 years ago.
Operating In more than 130 Countries with over
70,000 Employees.
Business Operations
Pharmaceuticals
Nutritional
Diagnostics
Diabetes Care

5. Abbott Pakistan is a part of the Global
Health Care Corporation of Abbott
Laboratories, Chicago, USA.
Started operations in Pakistan in 1948.
Along with 1500 Employees with 2
Locations Abbott is discovering new
Medicines
Technologies
Ways
To manage „Health‟

6. “To be a premier healthcare
company in Pakistan”

7. „A Promise for Life‟
Turning Science into Caring

8. Pioneering
 Leading edge Science &
Commercialization
Achieving
 World-Class Execution.
Caring
 Making a difference in people‟s lives.
Enduring
 Commitment & purpose.

9. Manufacturing more than 160 products
A broad range Including
 Pharmaceutical Products
 General Health Care Products
 Nutritional Products
 Diagnostics Products
 Diabetes Care

10. Pharmaceuticals Products

11. General Health Care
Products

12. Nutritional Products

13. Diagnostics Products

14. Diabetes Care

15. Abbott acquired Knoll BASF Pharma in
2000 for $6.9 billion.
On June 2005 Abbott achieved class „A‟
accreditation against Oliver Wight ABCD
checklist.

16. Strengths
Good company Reputation
Strong Distribution Network
Strong Brand positioning
Deep roots in Pharma business
Professional Management Team

17. Weaknesses
Comparatively High Prices
Relying on Imported Raw Material
Lacking of deep rural penetration

18. Opportunities
A part of high potential Economy
High rate of population increase in
Pakistan
Increasing Healthcare awareness

19. Threats
High Inflation rate
Foreign exchange rate
Political condition of Pakistan
Govt restriction on price

20. The Pakistan pharmaceutical industry meets
around 70% of the country‟s demand of
finished medicine
With an export turnover of over US $ 100
million as of 2007.
Market Share divided into 59% Local 41%
multinational

21. 7.6
4.3
3.9
5.9
0
1
2
3
4
5
6
7
8
GSK Highnoon Labs Getz Pharma Abbott Lab
Market Share
GSK
Highnoon Labs
Getz Pharma
Abbott Lab
59% Local 41% multinational
SOME MAJOR PLAYERS IN PHARMA INDUSTRY

22. 1st Qtr
21%
2nd Qtr
43%
3rd Qtr
Aug,2010
36%
4th Qtr
0%
Sales 2010
YEAR PROFIT AFTER TAXATION
(3rd Quarter)31 Aug-2010 Rs. 315,000,000
(2nd Quarter & Half ended) May
31st, 2010.
Rs. 339,047,000
(1st Quarter) February 28, 2010. Rs. 184,519,000

23. YEARS TOTAL SALES
(Rs in 000)
PROFIT Rs 000
(after taxation)
Net Profit to
Sales %
2009 8,450,118 825,676 9.8
2008 7,123,412 343,980 4.8
2007 6,584,454 1,184,762 18.0
2006 5,914,181 1,000,008 16.9
9.80%
4.80%
18%
16.90%
0.00% 5.00% 10.00% 15.00% 20.00%
2009
2008
2007
2006
Net Profit to Sales
Net Profit to Sales %

24. 38.50%
22.41%
0.03%
44.35%
0.10%
To Employees
To Government
To Society
To Providers of
Capital
To Providers of
Finance
2009 Spendings
2009

25. •No Doubt upon Company‟s ability to
Continue as a going concern.
•Assets Rs. 4.9 Billion(2009)
•Cash in Hand only Rs. 770 Million(2009)